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Objective. Costimulatory receptor CD226 plays
an important role in T cell activation, differentiation,
and cytotoxicity. This study was undertaken to investi-
gate the genetic association of CD226 with susceptibility
to systemic lupus erythematosus (SLE) and to assess
the functional implications of this association.
Methods. Twelve tag single-nucleotide polymor-
phisms (SNPs) in CD226 were typed in 1,163 SLE
patients and 1,482 healthy control subjects from Europe
or of European ancestry. Analyses of association were
performed by single-marker Cochran-Mantel-Haenszel
meta-analysis, followed by haplotype analysis. Gene
expression was analyzed by quantitative real-time poly-
merase chain reaction analyses of RNA from peripheral
blood mononuclear cells, and by fluorescence-activated
cell sorter analysis. To study the functional impact of
the associated variants, luciferase reporter constructs
containing different portions of the 3-untranslated
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region (3-UTR) of the gene were prepared and used in
transfection experiments.
Results. A 3-variant haplotype, rs763361;
rs34794968;rs727088 (ATC), in the last exon of CD226
was associated with SLE (P  1.3  104, odds ratio
1.24, 95% confidence interval 1.11–1.38). This risk hap-
lotype correlated with low CD226 transcript expression
and low CD226 protein levels on the surface of CD4
and CD8 T cells and natural killer T (NKT) cells. NK
cells expressed high levels of CD226, but this expression
was independent of the haplotype. Reporter assays with
deletion constructs indicated that only the presence of
rs727088 could account for the differences in the levels
of luciferase transcripts.
Conclusion. This study identified an association
of CD226 with SLE in individuals of European ancestry.
These data support the importance of the 3-UTR SNP
rs727088 in the regulation of CD226 transcription both
in T cells and in NKT cells.
Systemic lupus erythematosus (SLE) is a proto-
typical autoimmune disease with a wide range of clinical
manifestations. It is characterized by the production of
autoantibodies against nuclear antigens and increased
apoptosis of leukocytes, together with impaired mecha-
nisms of clearance, which leads to the formation and
deposition of immune complexes in multiple organs. The
disease has a complex inheritance, with a number of
genes contributing to susceptibility to SLE. In addition,
some of the implicated genes are shared with other
autoimmune diseases, which suggests that there are
common pathogenic pathways (1).
A recent genome-wide association study in pa-
tients with type 1 diabetes identified a susceptibility,
nonsynonymous risk variant in CD226 (rs763361/
Gly307Ser) (2), located on chromosome 18q22.3 (3). The
association of rs763361 has been further observed re-
cently in studies of patients with multiple sclerosis,
autoimmune thyroid disease, rheumatoid arthritis, and
Wegener’s granulomatosis (4,5). However, whether
CD226 is a susceptibility gene for SLE is not yet known.
Interestingly, CD226 levels on the surface of T cells are
altered in SLE patients (6). Moreover, CD226 expres-
sion is specifically down-regulated in natural killer T
cells (NKT cells) in patients with active SLE, which, in
turn, is correlated with increased sensitivity of these cells
to anti-CD95–induced apoptosis (7).
CD226, a type I transmembrane receptor of the
immunoglobulin superfamily that has 2 immuno-
globulin-like extracellular domains, is predominantly
expressed on the surface of T cells and NK cells and is
also present on monocytes, platelets, a subset of B cells
(3), mast cells (8), and megakaryocytes (9). CD226 is
involved in the activation and differentiation of T cells
(10–12), adhesion and cytotoxicity of T cells and NK
cells (3,13), apoptosis (7,14), transendothelial migration
of monocytes (15), and activation and aggregation of
platelets (16,17).
CD226 recognizes, with similar binding affinity, 2
ligands present on the target cells: nectin-2/CD112 and
poliovirus receptor/CD155 (18,13). Engagement with
the ligands induces phosphorylation of the cytoplasmic
domain by protein kinase C (19) and by the Src family
kinase Fyn (20), which provides a costimulatory signal
for activation of T and NK cells (11).
In the present study, we identify, for the first
time, an association of CD226 with SLE in patients of
European ancestry through a risk haplotype located in
the 3-untranslated region (3-UTR). In addition, we
demonstrate that the risk allele C of rs727088 is respon-
sible for the reduced gene expression of CD226 in T and
NKT cells.
PATIENTS AND METHODS
Patients and controls. After quality control of the data,
the cohort consisted of 1,163 patients with SLE and 1,482
ethnicity-matched healthy control subjects from the European
multicenter collaboration (see Appendix for the collaborative
group participants) known as the BIOLUPUS network (sup-
ported by the European Science Foundation), comprising
individuals from Argentina (60 patients and 109 controls),
Belgium (70 patients and 59 controls), Germany (284 patients
and 176 controls), Hungary (38 patients and 35 controls), Italy
(264 patients and 320 controls), Portugal (163 patients and 165
controls), Spain (206 patients and 227 controls), and Sweden
(78 patients and 391 controls). All of the individuals from
Argentina had85% European ancestry. Patients who did not
fulfill at least 4 of the American College of Rheumatology
1982 criteria for the classification of SLE (21) were excluded
from the study. In addition, subjects with an individual geno-
typing rate lower than 90%, as well as duplicated and/or
related samples, were excluded. Non-European individuals
(n  61), who were identified by principal components analy-
sis, were also removed from the study cohort.
Single-nucleotide polymorphism (SNP) selection.
From the linkage disequilibrium (LD) structure of the CD226
locus in the HapMap CEU population (data release 27;
available at http://hapmap.ncbi.nlm.nih.gov/), 12 tag SNPs
capturing the variation at the gene locus including 20 kb
upstream and downstream of the gene, with a minor allele
frequency of greater than or equal to 10% and an r2 threshold
of greater than or equal to 0.8, were selected using the tagger
algorithm implemented in Haploview, version 4.1 (22). The
rs763361 SNP was forced-included in the list of SNPs.
Genotyping. All samples were genotyped at the Fein-
stein Institute for Medical Research (Manhasset, NY) using a
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GoldenGate Custom Genotyping Assay and a BeadXpress
Reader from Illumina. Three SNPs (rs727088, rs34794968, and
rs763361) were genotyped by TaqMan 5-exonuclease assay
(Applied Biosystems) at Uppsala University and at the Insti-
tuto de Biomedicina y Parasitologı´a Lo´pez-Neyra in Granada
(for all samples from Spanish subjects). Genotyping consis-
tency between the centers has been established as being near
100% (23).
Genetic association analysis. The genetic association
analysis was done using PLINK software, version 1.07 (24).
First, all SNPs with a genotype call rate lower than 95% or
those not in Hardy-Weinberg equilibrium (P  0.001) were
excluded. For the single-marker tests, we performed a
Cochran-Mantel-Haenszel (CMH) meta-analysis, using the
country of origin as the stratification variable, and also per-
formed a Breslow-Day test to assess the homogeneity of the
odds ratios (ORs). In addition, we performed a haplotype
analysis of the 3-UTR block, including a general, or omnibus,
test, a sliding window analysis with 2 SNPs and 3 SNPs, and
haplotype-specific association tests implemented in PLINK
(24). The omnibus haplotype test is a global test of association
in which the alternate hypothesis of each haplotype having a
unique effect is compared with the null hypothesis of no
haplotypes having any different effect (24). The haplotype-
specific analysis involves testing of each haplotype against all
others pooled together (1 df) (24), and interpretation of the
ORs derived from this test must take into account the fact that
there is no single reference haplotype in the analysis. Alterna-
tive genetic models (additive, dominant, and recessive) for the
haplotype association were tested by logistic regression using
R, version 2.9.2.
For analyses of RNA expression and fluorescence-
activated cell sorter (FACS) analyses, statistical calculations
were performed using an unpaired 2-tailed t-test with Graph-
Pad software (available at http://www.graphpad.com). The
correlation between relative expression levels of RNA and
genotypes was analyzed by linear regression using PLINK
software, version 1.07. The original expression data were
normalized using an exponential transformation (log normal
distribution).
Transcript analysis and gene resequencing. We per-
formed analysis of all gene transcripts expressed in the sub-
jects’ peripheral blood mononuclear cells (PBMCs) and in
samples of human thymus (Clontech). Primers specific to
different areas of the coding region were as follows: for
forward primers, forward transcript CD226, GCGTTAGAGC-
GAGCAGCACTCACATCTC, forward exon 2, TCAAA-
CAGTTTCCAGAGATGGATTA, and forward cd226, CGT-
GATGAGATTGACTGTAGCCGA; for reverse primers,
reverse transcript CD226, GCTTAATCTCCCCTGGATCAT-
TCTG, reverse cd226, GGGTGCCTTCTGTGTATCCCAG,
and reverse exon 3, AGGGAACTGATGTATGCCAAAGC.
Commercial common adapter primers Ap1 and Ap2 were used
for polymerase chain reaction (PCR) analysis of human thy-
mus complementary DNA (cDNA). The GenBank accession
number for the novel alternative exon2–3 transcript is
GU935336. Approximately 500 bp of the promoter region,
exon 1, exons 2 and 3, exons 5 and 7, and 500 bp of the
adjacent introns, as well as the region downstream of the gene,
were sequenced in samples from 35 individuals of Swedish
origin.
Analysis of CD226 messenger RNA (mRNA) expres-
sion. Total RNA was purified with TRIzol reagent (Invitrogen)
from PBMCs obtained from 84 healthy donors of Swedish
origin. Synthesis of cDNA was performed at 42°C for 80
minutes using 2 g of RNA, 5 M oligo(dT) primer, Moloney
murine leukemia virus transcriptase, and RNase inhibitor in
buffer supplemented with 5 mM MgCl2 and 1 mM dNTP. The
TRIzol interphase left after RNA purification was used for
purification of genomic DNA for further genotyping and
cloning.
CD226 expression was determined by quantitative real-
time PCR on a 7900HT Sequence Detection System (Applied
Biosystems) with version 2.2.2 software, using SYBR Green for
signal detection. The following primer pairs were used: for-
ward CGTGATGAGATTGACTGTAGCCGA, and reverse
GGGTGCCTTCTGTGTATCCCAG. Initial denaturation at
95°C for 5 minutes was followed by 45 cycles comprising 95°C
for 15 seconds, 66°C for 15 seconds, and 72°C for 15 seconds.
The PCR buffer was supplemented with 1.5 mM MgCl2, 200
M dNTP, primers, SYBR Green (Molecular Probes), 15 ng of
cDNA, and 0.5 units of Platinum Taq polymerase (Invitrogen).
Expression levels were normalized to the gene coding for
TATA-binding protein (TBP) using the comparative 2Ct
method (25). Real-time PCR for TBP was performed with
commercial reagents (Applied Biosystems). All experiments
were run in triplicate.
Cell preparation and FACS analysis of CD226 surface
expression. Freshly collected buffy coats, obtained at the
Uppsala University Hospital from 100 healthy donors, were
aliquoted and immediately frozen in liquid nitrogen with 10%
DMSO (Sigma). An aliquot was used for DNA purification
and subsequent genotyping. Frozen cells that had been ob-
tained from individuals with known genotypes (total of 22
individuals; 8 women and 14 men) were thawed, and leuko-
cytes were purified from erythrocytes by lysing in ACK lysing
buffer (Gibco) for 4 minutes, followed by centrifugation at
500g for 5 minutes, washing in phosphate buffered saline
(PBS) buffer, and staining with antibodies for FACS analysis.
Three-color flow cytometry was used for quantitative
measurement of CD226 in total lymphocytes, CD3CD4 T
cells, CD3CD8 T cells, CD3CD19 B cells,
CD3CD56 NK cells, and CD3CD56 NKT cells. Puri-
fied leukocytes were resuspended in PBS and incubated with
different combinations of antibodies: phycoerythrin (PE)–
Cy5–conjugated CD3 (clone HIT3a), fluorescein isothiocya-
nate (FITC)–conjugated CD4 (RPA-T4), FITC-conjugated
CD8 (RPA-T8), Alexa Fluor 488–conjugated CD56 (B159),
allophyocyanin-Cy7–conjugated CD19 (HIB19), and PE-
conjugated CD226 (DX11) for 30 minutes at room tempera-
ture. Background fluorescence was assessed using appropriate
isotype- and fluorochrome-matched control antibodies. All
antibodies were purchased from BD Biosciences, except for
HIB19, which was obtained from BioLegend. Twenty thousand
lymphocytes were acquired on an LSR II FACS using DiVA
software (BD Biosciences), and data analysis was performed
using FlowJo software (TreeStar).
Reporter constructs and luciferase assays. The entire
exon 7 coding for the 3-UTR region and 500 bp of the
downstream sequence of the human CD226 gene was ampli-
fied by PCR analysis of samples from individuals with known
genotypes. The following primers were used: forward GCAC-
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CCAATAACTATAGAAGTCCCATC, and reverse TATAC-
CTGGATTCATGAAATGT. Pfu Ultra II Fusion HS DNA
polymerase was used with Pfu Ultra II buffer (Stratagene)
supplemented with 200 M dNTP (Invitrogen), primers, and
15 ng of genomic DNA. Initial denaturation at 95°C for 5
minutes was followed by 30 cycles comprising 95°C for 15
seconds, 60°C for 15 seconds, and 72°C for 2 minutes. The
PCR products were purified from gel and were then cloned in
the pGL3-promoter vector (Promega) by replacing the vector’s
original SV40 late poly(A) sequence. The constructs with the
full-length 3-UTR and 3 more deletion constructs for each
allele were prepared and verified by sequencing.
Subsequently, 800 ng of the luciferase reporter con-
structs were cotransfected together with 10 ng pRL-TK vector
(Promega) in 3 	 105 HEK 293 T cells using Lipofectamine
2000 (Invitrogen). Thirty hours after transfection, cells were
collected, washed with PBS, and then lysed in Passive Lysis
Buffer (Promega). Ten microliters of the protein lysates was
assayed with a dual-luciferase reporter assay system (Pro-
mega). Values for luciferase activity were normalized, with
results expressed as the ratio of Firefly to Renilla luciferase
units. Independent plasmid purifications, transfections, and
luciferase assays were repeated 4 times.
Assessment of RNA degradation rates. The kinetics of
mRNA degradation were measured after treatment of the cells
with actinomycin D. Briefly, 30 hours after transfection with
the reporter constructs, cells were treated with 10 g/ml of
actinomycin D (Sigma) and collected at 0, 2, 4, 8, and 12 hours
thereafter. RNA and DNA were purified using TRIzol and
then processed for quantitative real-time PCR. In order to
control for transfection efficiency, transcript levels were nor-
malized to the levels of plasmid DNA assessed by quantitative
PCR. The following primers matching to the luciferase gene
were used for both RNA and DNA PCRs: forward CATTC-
TATCCGCTGGAAGATGGAAC, and reverse TCATAGCT-
TCTGCCAACCGAACG.
RESULTS
Association of CD226 with susceptibility to SLE.
To examine the role of CD226 in SLE, we first per-
formed a search for new common variants in the gene by
sequencing 500 bp from the proximal promoter, exon 1,
exons 2 and 3, exons 5 and 7, 500 bp of the intronic
sequence surrounding each exon, and 500 bp down-
stream of the gene in 35 individuals. Two insertion/
deletions were identified. Deletion GGGGGCT, located
downstream of exon 1, was present in all of the samples,
and insertion/deletion AGTG, located 223 bp down-
stream of the gene, displayed a pattern correlating with
SNP rs727088, the closest variant located in the 3-UTR
of CD226. The C allele of rs727088 correlated with the
presence of the insertion, while the T allele correlated
with the deletion. No other polymorphisms in the se-
quenced regions were found.
We next genotyped 12 tag SNPs, including
rs763361, and tested for associations in 1,163 SLE patients
and 1,482 ethnicity-matched healthy controls (Table 1).
Association analyses revealed that the strongest significant
signal was in exon 7 of CD226 (for rs763361, corrected P
value in the CMH meta-analysis [PCMH-corrected]  0.0105,
OR 1.20, 95% confidence interval [95% CI] 1.07–1.35); for
rs34794968, PCMH-corrected  0.0299, OR 1.17, 95% CI
1.04–1.31; and for rs727088, PCMH-corrected  0.0105, OR
1.21, 95% CI 1.08–1.36). These 3 SNPs were strongly
correlated and were part of a 5-SNP haplotype block
covering the last exon and 5 kb downstream of the gene
Table 1. Association analysis of CD226 single-nucleotide polymorphisms (SNPs) with systemic lupus erythematosus*
SNP
Basepair
position† Location
Allele
A
Allele A
frequency
Allele
B OR 95% CI PCMH PCMH-corrected PBreslow-Day
Genotyping
rate, %
PHWE
vs.
controls
rs12604328 65675953 Downstream C 0.29 T 1.18 1.04–1.33 0.0100 0.0299 0.1202 99.74 0.8455
rs1469858 65680197 Downstream T 0.43 C 1.15 1.03–1.29 0.0144 0.0344 0.2197 99.89 0.5563
rs727088 65681419 Exon 7 C 0.50 T 1.21 1.08–1.36 9.57 	 104 0.0105 0.1812 97.88 0.3711
rs34794968 65682006 Exon 7 T 0.42 G 1.17 1.04–1.31 8.51 	 103 0.0299 0.1320 98.79 0.7454
rs763361 65682622 Exon 7 A 0.50 G 1.20 1.07–1.35 1.74 	 103 0.0105 0.1366 98.83 0.2499
rs1124980 65699607 Intron 4 C 0.43 T 1.15 1.02–1.29 0.0180 0.0359 0.5640 99.92 0.8304
rs12969613 65710412 Intron 4 T 0.49 A 1.13 1.01–1.27 0.0331 0.0496 0.1627 99.92 0.4351
rs17208329 65716443 Intron 3 T 0.23 C 1.10 0.96–1.26 0.1732 0.2079 0.2659 99.85 0.7099
rs17842596 65716559 Intron 3 C 0.42 T 1.11 0.99–1.25 0.0745 0.0993 0.1146 99.81 0.5899
rs1788234 65717567 Intron 3 T 0.40 C 1.14 1.02–1.28 0.0255 0.0438 0.1662 99.47 0.0912
rs10432228 65719229 Intron 3 C 0.32 T 1.00 0.89–1.13 0.9424 0.9424 0.4305 99.96 0.1894
rs11151547 65751971 Intron 3 C 0.47 T 1.06 0.94–1.19 0.3400 0.3709 0.8565 99.85 0.2496
* The odds ratios (ORs) (with 95% confidence intervals [95% CIs]) were calculated for the frequency of allele A in each SNP, determined using
a Cochran-Mantel-Haenszel meta-analysis with the country of origin as the stratification variable. The value PCMH indicates the significance of the
allelic association determined by the Cochran-Mantel-Haenszel meta-analysis, while PCMH-corrected displays the association after adjustment for false
discovery rate, and PBreslow-Day is the P value determined using the Breslow-Day test for homogeneity of the ORs. PHWE is the P value testing for
Hardy-Weinberg equilibrium in patients compared with healthy controls. The analyses were performed using PLINK software, version 1.07 (24).
† Obtained from the National Center for Biotechnology Information Build 36.
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(Figure 1A). The 5-SNP haplotype block was associated
with disease status (P  0.0163, by omnibus test).
The high correlation between the alleles of these
SNPs made it difficult to discern the true susceptibility
variant, and therefore, in an attempt to dissect the
association of this block, we performed several haplo-
type tests. First, we examined whether any SNP had an
effect independent of the haplotype background. How-
ever, this was not possible to test, due to the high LD
between the SNPs, which thus meant the absence of
common haplotypes (those with a frequency of 0.05)
containing all of the possible allele combinations. We
then tested for association using a sliding window of 2
and 3 SNPs, which narrowed down the association
region to the 3-UTR in between SNPs rs34794968 and
rs727088, since both were included in the 2 best windows
(Figure 1B). The best model of association was observed
in the haplotype combination rs763361;rs34794968;
rs727088 (P  8.63 	 104, by omnibus test). These
variants formed 3 common haplotypes: GGT, ATC, and
AGC (Table 2). By testing each haplotype against all
others, only one, ATC, was found to be consistently
associated with SLE (P 1.30	 104, OR 1.24, 95% CI
1.11–1.38).
We also tested alternative genetic models. The
association of the haplotype ATC fitted an additive
model best (P  0.000123). However, the recessive
model showed the strongest impact in terms of the effect
size (P  0.0011, OR 1.40 95% CI 1.14–1.71).
CD226 mRNA expression in leukocytes. In order
to determine whether the associated 3-UTR haplotype
correlated with gene expression, we measured CD226
mRNA expression levels in the PBMCs of healthy
donors. We first performed analysis of all gene tran-
scripts expressed in PBMCs and samples of human
thymus. Two alternative transcripts were detected in the
Figure 1. Association of the 3–single-nucleotide polymorphism (SNP)
haplotype in the 3-untranslated region (3-UTR) of CD226 with systemic
lupus erythematosus (SLE). A, Linkage disequilibrium structure of
CD226, as determined using Haploview, version 4.1 (22). Blocks were
defined by the solid spine method. B, Analysis of haplotypes by sliding
windows analysis of 2-SNP haplotypes and 3-SNP haplotypes. The y-axis
shows the log10 P values for only the haplotype windows significantly
associated (P  0.05) with SLE, while the x-axis shows the 12 SNPs
genotyped across CD226 plus 5 kb downstream of the gene (as identified
in the National Center for Biotechnology Information Build 36). Relative
SNP positions are mapped on the gene, with coding exons shown in red
and noncoding exons shown in blue. The direction of transcription is
shown by the arrow. The enlargement of the 3 region highlights the 3
SNPs giving the best association: rs763361, rs34794968, and rs727088.
Table 2. Association of the CD226 haplotype block rs763361–
rs727088 in exon 7
Frequency
P OR (95% CI)Cases Controls
Global* 5.26 	 104
Haplotype-specific†
GGT 0.479 0.511 0.100 0.91 (0.82–1.02)
ATC 0.443 0.397 1.30 	 104 1.24 (1.11–1.38)
AGC 0.078 0.091 0.122 0.868 (0.70–1.00)
* The global P value indicates the overall significance of the associa-
tion of the rs763361;rs34794968;rs727088 haplotype, determined using
the omnibus haplotype test of association.
† In haplotype-specific analyses, the odds ratio (OR) with 95% confi-
dence interval (95% CI) was determined for each allele variant in
haplotype rs763361;rs34794968;rs727088 tested against all of the oth-
ers pooled together. For this test, there is no single reference
haplotype, and the OR must be interpreted in this context. All analyses
were performed using PLINK software, version 1.07 (24).
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PBMCs: the full-length isoform, and the exon2–3
isoform (lacking exons 2 and 3). The presence of the
exon2–3 transcript, which, because of exon-skipping,
contains a shift in the translational-reading frame, may
lead to the premature termination of protein synthesis.
We evaluated the relative amounts of the transcripts and
found that exon2–3 transcripts were present at very low
levels when compared with those of the full-length
isoform (results not shown).
We next analyzed the expression of the full-
length isoform of CD226 in the PBMCs of healthy
individuals, in whom different 3-UTR haplotypes were
present. In total, the analysis included 13 individuals
who were homozygous for the haplotype ATC (ATC/
ATC), 38 in whom only 1 copy of the ATC haplotype
plus any other haplotype was present (ATC/other), and
33 in whom either GGT or the low-frequency AGC
haplotype, but no copies of the ATC haplotype, was
present (other/other). We found that individuals ho-
mozygous for the risk haplotype ATC expressed the
lowest CD226 transcript levels (P  0.02357) compared
with the heterozygous group or those homozygous for
other haplotypes (Figure 2A). This result suggests that
there is a recessive effect of the ATC haplotype on gene
expression levels. We also tested these associations in
the additive and dominant models, but neither yielded
significant results (P  0.083 and P  0.415, respec-
tively).
Surface expression of CD226 protein. For mea-
surement of CD226 protein expression on the surface of
different populations of lymphocytes from individuals
with different haplotypes, we used FACS analysis. The
highest levels of surface expression of CD226 were
observed on NKT cells, cytotoxic T cells, and NK cells.
We observed that individuals with the haplotype ATC
had significantly lower surface expression of CD226 than
did individuals with the GGT haplotype, specifically in T
helper cells (CD3CD4) (P  0.0022), T cytotoxic
cells (CD3CD8) (P  0.0295), and NKT cells
(CD3CD56) (P  0.0264) (Figure 2B). None of the
individuals had the low-frequency haplotype AGC in the
cell analysis. Both the mean values for CD226 surface
expression and the lack of statistically significant differ-
ences in expression between the GGT haplotype and the
heterozygote haplotypes further confirmed the signifi-
cance of the recessive model observed in the RNA
expression analysis.
The number of cells staining positive for CD226
was similar among individuals with different genotypes,
indicating that the correlation of the down-regulation of
CD226 expression with the risk haplotype was not
attributable to reduced cell numbers in any of the
Figure 2. Differential expression of CD226. A, For analysis of CD226 mRNA expression in peripheral blood
mononuclear cells from healthy donors, samples were stratified according to haplotypes made up of rs763361,
rs34794968, and rs727088. A recessive genetic effect is shown by the significant difference in mRNA expression between
the ATC/ATC homozygotes and those with the ATC/Other or Other/Other haplotypes (includes GGT and the
less-frequent AGC). Bars show the mean 
 SD relative mRNA levels normalized to the housekeeping gene coding for
the TATA-binding protein. B, Surface expression of CD226 protein was analyzed by fluorescence-activated cell sorter
analysis in T helper (CD4) cells (Th), T cytotoxic (CD8) cells (Tc), natural killer T (CD3CD56) cells (NKT), and
natural killer (CD3CD56) cells (NK) from individuals grouped according to A/A-T/T-C/C homozygotes (n  7),
A/G-G/T-T/C heterozygotes (n 5), and G/G-G/G-T/T homozygotes (n 7). Bars show the mean. Differences in mean
values between the ATC and GGT groups were as follows: P  0.0022 for Th cells, P  0.0295 for Tc cells, P  0.0264
for NKT cells, and P  0.7092 for NK cells. MFI  mean fluorescence intensity.
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analyzed subpopulations but rather to a transcriptional
down-regulation of CD226. Interestingly, staining with
anti-CD226 antibodies revealed the presence of 2 sub-
populations of CD4 T cells that differentially ex-
pressed CD226 (Figure 3). Moreover, CD226 expression
in the CD4 cell subsets correlated with haplotype, in
that cells from individuals with the low-risk GGT hap-
lotype displayed a major subset of CD4 cells producing
high levels of CD226 and a small fraction of cells
producing lower levels, while the opposite pattern was
observed in those with the high-risk ATC haplotype.
Although NK cells expressed high amounts of surface
CD226, comparable with that in CD8 cells, we could
not detect any difference in expression in this cell
population between individuals with the low-risk haplo-
types and those with the high-risk haplotype (P 
0.7092). Furthermore, no difference in expression was
observed in B cells (results not shown).
Minigene analysis of the SNPs in the 3-UTR.
Our association analysis clearly pointed to the last exon
of CD226 between the SNPs rs763361 and rs727088 as
the region with the strongest association with SLE. In
order to study the independent functional impact of the
polymorphisms on gene expression, we prepared 2
haplotype-specific reporter constructs with firefly lucif-
erase and the entire 3-UTR sequence from the CD226
gene, along with the 500-bp region downstream of the
poly(A) site (Figure 4A). We prepared 3 more con-
structs for each haplotype, which included a sequential
deletion of the following regions: 1) deletion of 57
nucleotides from the 5-end, thus lacking SNP rs763361
(76), 2) deletion of the upstream region, including SNP
rs34794968 (347), and 3) deletion of the region up-
stream and downstream of rs727088, including the
insertion/deletion (short). Constructs were transfected
in HEK 293 T cells, and 30 hours later, the activity of
luciferase was measured in the protein lysates.
Analysis of these deletion constructs indicated
that rs727088 was still significantly associated with dif-
ferential expression of the luciferase reporter after all
other variants were excluded from the construct (P 
0.01). In contrast, removal of rs763361, located at the
beginning of exon 7 and previously suggested to function
in regulation of transcription (4), had no impact on the
difference in the levels of luciferase detected. Thus, the
evidence suggests that only rs727088, located 245 bp
upstream of the poly(A) signal, accounts for the differ-
ence in the levels of luciferase transcripts.
Analysis of RNA degradation rate. To investigate
the effect of the polymorphisms on RNA turnover, we
performed an RNA degradation experiment using 2
haplotype-specific constructs: 76-T, containing the G
allele of rs34794968, the T allele of rs727088, and the
deletion, and 76-C, containing the T allele of
Figure 3. Fluorescence-activated cell sorter (FACS) analysis of CD226 surface staining. FACS histograms show the log mean
fluorescence intensity values (determined by staining with phycoerythrin-conjugated CD226 antibodies [CD226-PE]) plotted against
the cell counts for the cell subpopulations CD3CD4, CD3CD8, and CD3CD56 in individuals with either the ATC
haplotype or GGT haplotype, compared with isotype control. Results are from 1 representative individual of 7 in each genotype group,
and percentages of positive cells are shown as averages. The gray-scale density plots on the right side of the CD3CD4 histogram
show the relative frequencies of subpopulations of CD4 cells expressing CD226. The red arrows indicate the 2 varying subpopulations
observed in the individuals with the ATC or GGT haplotype.
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rs34794968, the C allele of rs727088, and the insertion.
We observed no difference in the luciferase mRNA
degradation rates between the experiments with each
construct (Figure 4B). Although the initial RNA levels
were different, the kinetics of degradation of RNA
bearing either the G-T–deletion or the T-C–insertion
haplotypes was similar, thus ruling out the possibility
that these polymorphisms determined the mRNA degra-
dation rate.
DISCUSSION
Our results provide strong evidence to support
the association of SLE with CD226, a gene that has been
reported to be associated with other autoimmune dis-
eases. We identified a susceptibility haplotype located in
the last exon that was formed by 3 highly correlated
variants: the rs763361 (Gly307Ser) variant, rs34794968,
and rs727088. SNP rs727088 is a novel functional variant
that was responsible for reduced gene expression. There
are several possible reasons to explain why this variant
was not identified before. First, the replication study in
patients with type 1 diabetes and those with multiple
sclerosis (4), which was based on tag SNPs, did not
directly test this variant, most likely because of the
complete LD reported in the HapMap CEU population
between rs763361 and rs727088. Second, a subsequent
association study analyzing an association between
CD266 and Wegener’s granulomatosis or multiple scle-
rosis included only the rs763361 variant (5). Although an
association with rs763361 was detected, it cannot be
ruled out that the significant result was due to the high
LD with rs727088.
The prior bias toward testing of rs763361 could
be attributed mainly to its location as a nonsynonymous
variant. Our previous studies on IRF5 genes (26) and
BANK1 genes (27), as well as the results of the present
study, show that a search for other variants, with a focus
on the regulatory ones, may lead to more comprehensive
understanding of the multiple functional alterations
possible within a single gene. We aimed to capture the
full genetic variation in the CD226 3-UTR, including
several correlated SNPs, so that we could best identify
the minimal region of association.
The LD between rs763361 and rs727088 was high
in our European cohort (r2  0.95) but slightly lower
than that in HapMap (r2  1.00). The high LD of the
region made it difficult to reliably discriminate the true
susceptibility variant, due to the lack of haplotypes
containing all of the possible allele combinations with a
frequency higher than 5%. The inclusion of very rare
haplotypes in the analysis introduces a statistical bias,
and for that reason, we instead performed functional
analyses, which allowed us to separate these alleles in
vitro and to better define their functional significance.
Among the tested cell populations, the highest
expression of CD226 was detected on the surface of
NKT cells. Moreover, our expression analysis revealed
that the risk haplotype ATC, containing the C allele for
rs727088, correlated with lower expression of CD226 in
T and NKT cells, but not in NK or B cells. Of note, Tao
Figure 4. Reporter analysis of the 3-untranslated region (3-UTR) of CD226. A, The entire exon 7 and 500 bp of the downstream
region were cloned and inserted after the firefly luciferase (F-luc) cDNA in a pGL3 vector. Left, Deletion () constructs of each of the
variants, except rs727088, are shown with the relative positions for rs763361 (A/G), rs34794968 (T/G), and rs727088 (C/T), along with
their respective insertion/deletion (ins/del). Right, The relative luciferase activity units of each construct are shown. Bars show the
mean 
 SD results from 4 independent experiments. In experiments with the firefly luciferase (FL) constructs, P  0.02 for G-G-T-del
versus A-T-C-ins; in those with 76, P  0.007 for G-T-del versus T-C-ins; in those with 347, P  0.003 for T-del versus C-ins; and
in those with the short constructs, P  0.01 for short T versus short C. B, The kinetics of luciferase mRNA degradation in experiments
using the 2 reporter constructs, 76 with the alleles G-T-del and 76 with the alleles T-C-ins, were measured after treatment of the
cells with actinomycin D. Normalized transcript levels are shown (left), as well as transcript levels as a percentage of the initial RNA
(right). Bars show the mean 
 SD.
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et al (7) reported that CD226 was down-regulated
specifically on NKT cells of patients with active SLE,
suggesting a unique role for these cells in the disease.
They found that NKT cells from patients were highly
sensitive to apoptosis mediated by the CD95–CD95L or
T cell receptor–CD3 pathways. It was demonstrated also
that preactivation of CD226 with anti-CD226 antibodies
can rescue activated T cells from apoptosis (7).
Reduced numbers and impaired functions of
NKT cells were found in both human and mouse lupus
(28–33). NKT cells, a subset of regulatory T lympho-
cytes, are known to control various immune reactions
and have been shown to promote immune tolerance
(34–38). Recently, Hegde et al (39) have shown that
NKT cells may instruct peripheral blood monocytes to
develop into myeloid antigen-presenting cells (APCs)
with suppressive function and high interleukin-10 pro-
duction. Furthermore, these APCs silenced T cell re-
sponses and inhibited interferon- secretion. It has also
been observed that NKT cells promote differentiation
toward Th2 cells and suppress antibody production in
marginal zone B cells in mice (40–42). Thus, the poten-
tial role of CD226 in the pathogenesis of autoimmunity
might be related to NKT cell–mediated functions. Lower
expression of CD226 in susceptible individuals, together
with the overall reduction in the NKT cell population,
possibly as a result of increased apoptosis, may lead to
sustained activation of T cells and thus promote devel-
opment of autoimmune disorders.
It was previously suggested that the SNP
rs763361, located in the beginning of the last exon of
CD226, might affect splicing by modifying either exonic
splicing enhancers or silencers (2,4). In our study, the
removal of the region containing this SNP in the re-
porter constructs did not reduce the difference in the
levels of luciferase, as would be expected if rs763361
were the variant affecting expression. Thus, it is evident
that splicing efficiency is unlikely to be the reason for the
altered CD226 expression in SLE. An alternative CD226
isoform lacking exon 3 was reported to be present in
mice (43). We detected low levels of an isoform lacking
exons 2 and 3, which thus generated an untranslated
transcript.
However, we cannot exclude the possibility that
rs763361 may exert an effect at the protein level by
strengthening the adjacent serine–threonine phosphor-
ylation sites Ser302, Ser305, and Thr306 in the cytoplasmic
domain of the receptor, as can be predicted using the
NetPhosK server program (available at http://
www.cbs.dtu.dk/services/NetPhosK/), although this
needs to be investigated empirically. Nevertheless,
changes in protein phosphorylation could not account
for the observed reduction in CD226 transcript levels.
Results of the reporter assays indicated that, rather,
another SNP, rs727088, is the main variant responsible
for the differential gene expression. SNP rs727088 is
located 245 bp upstream of the polyadenylation signal
and thus may influence the efficiency of transcription
termination. We found that RNA turnover was essen-
tially similar for 3-UTRs with both alleles. At present,
the molecular mechanism whereby rs727088 affects the
transcription of CD226 needs to be elucidated, especially
considering the cell-specific effect of the polymorphism.
In summary, we have identified an association of
CD226 with SLE in individuals of European ancestry.
Our data support the importance of the 3-UTR SNP
rs727088 for the regulation of CD226 transcription in T
and NKT cells.
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APPENDIX A: PARTICIPANTS IN THE
COLLABORATIVE GROUPS
Participants in the Spanish Collaborative Group are Norberto
Ortego-Centeno and Jose L. Callejas (Hospital Clı´nico San Cecilio,
Granada), Mayte Camps (Hospital Carlos Haya, Malaga), Juan
Jime´nez-Alonso (Hospital Virgen de las Nieves, Granada), Julio
Sa´nchez-Roma´n and Francisco J. Garcı´a-Hernandez (Hospital Virgen
del Rocio, Seville), and Miguel Angel Lo´pez-Nevot (Hospital Virgen
de las Nieves, Granada). Participants in the Argentine Collaborative
Group are Hugo R. Scherbarth, Pilar C. Marino, and Estela L. Motta
(Hospital Interzonal General de Agudos “Dr. Oscar Alende,” Mar del
Plata), Susana Gamron, Cristina Drenkard, and Emilia Menso (Hos-
pital Nacional de Clı´nicas, Universidad Nacional de Co´rdoba, Co´r-
doba), Alberto Allievi and Guillermo A. Tate (Organizacio´n Me´dica
de Investigacio´n, Buenos Aires), Jose L. Presas (Hospital General de
Agudos Dr. Jua´n A. Fernandez, Buenos Aires), Simon A. Palatnik,
Marcelo Abdala, and Mariela Bearzotti (Universidad Nacional de
Rosario y Hospital Provincial del Centenario, Rosario), Alejandro
Alvarellos, Francisco Caeiro, and Ana Bertoli (Hospital Privado,
Centro Medico de Co´rdoba, Co´rdoba), Sergio Paira and Susana
Roverano (Hospital Jose´ M. Cullen, Santa Fe), Cesar E. Graf and
Estela Bertero (Hospital San Martı´n, Parana´), Cesar Caprarulo and
Griselda Buchanan (Hospital Felipe Heras, Concordia, Entre Rı´os),
Carolina Guillero´n, Sebastian Grimaudo, and Jorge Manni (Instituto
de Investigaciones Me´dicas “Alfredo Lanari,” Buenos Aires), Luis J.
Catoggio, Enrique R. Soriano, and Carlos D. Santos (Hospital Italiano
de Buenos Aires y Fundacio´n Dr. Pedro M. Catoggio para el Progreso
de la Reumatologı´a, Buenos Aires), Cristina Prigione, Fernando A.
Ramos, and Sandra M. Navarro (Hospital Provincial de Rosario,
Rosario), Guillermo A. Berbotto, Marisa Jorfen, and Elisa J. Romero
(Hospital Escuela Eva Pero´n, Granadero Baigorria, Rosario), Mer-
cedes A. Garcia, Juan C. Marcos, and Ana I. Marcos (Hospital
Interzonal General de Agudos General San Martı´n, La Plata), Carlos
E. Perandones and Alicia Eimon (Centro de Educacio´n Me´dica e
Investigaciones Clı´nicas, Buenos Aires), and Cristina G. Battagliotti
(Hospital de Nin˜os Dr. Orlando Alassia, Santa Fe). Participants in the
Italian Collaborative Group are Nadia Barizzone (University of East-
ern Piedmont, Novara), Maria Giovanna Danieli (Universita` Politec-
nica delle Marche, Ancona), Gian Domenico Sebastiani (U.O.C. di
Reumatologia Ospedale San Camillo, Rome), Enrica Bozzolo and
Maria Grazia Sabbadini (IRCCS San Raffaele Hospital, Milan),
Mauro Galeazzi (Siena University, Siena), and Sergio Migliaresi and
Giovanni La Montagna (Second University of Naples, Naples).
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